NR1H4 and thrombotic disease: showed that bile salts are capable of inhibiting platelet aggregation in vitro.[26] For bile acid receptors, studies have found that the FXR ligand can inhibit platelet activation, which may be related to promoting coated platelet formation.[27, 28] However, the regulatory effects of different types of BAs on platelet activation, thrombotic diseases, and intracellular mechanisms have not been fully clarified, and further exploration is still needed.